Novartis Ag (NVSEF) Current Leases (2019 - 2026)

Novartis Ag has disclosed Current Leases across 8 years of filings, most recently posting $271.0 million for Q1 2026.

• Current Leases for Q1 2026 came in at $271.0 million, up 11.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $271.0 million (up 11.98% YoY), and the FY2025 annual result was $263.0 million, up 11.91% from the prior year.
• Current Leases came in at $271.0 million for Q1 2026 at Novartis Ag, up from $263.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.6 billion in Q2 2025 to a low of $210.0 million in Q3 2023.
• The 5-year median for Current Leases is $251.0 million (2022), against an average of $556.5 million.
• Across the five-year window, Current Leases retreated 15.32% in 2023 and grew 17.62% in 2024, its largest moves.
• Novartis Ag's Current Leases stood at $251.0 million in 2022, then dropped by 8.37% to $230.0 million in 2023, then increased by 2.17% to $235.0 million in 2024, then climbed by 11.91% to $263.0 million in 2025, then gained by 3.04% to $271.0 million in 2026.
• The last three Current Leases figures came in at $271.0 million (Q1 2026), $263.0 million (Q4 2025), and $264.0 million (Q3 2025), per Business Quant data.